Amneal Pharmaceuticals (AMRX) surged approximately 24% over the last 30 days, climbing from $13.71 on June 8 to $17.05 by July 7, 2026. The rally was fueled by a series of positive catalysts, including FDA approval of romidepsin injection solution, selection for the FDA PreCheck Pilot Program, and inclusion in multiple Russell 2000 Defensive indexes.

Alkermes shares surged approximately 27.6% over the past 30 days, climbing from $42.76 on June 3 to $54.57 as of July 2, 2026, driven by a series of positive clinical and regulatory catalysts for its lead orexin agonist, alixorexton. The stock has gained roughly 56% over the last quarter, reflecting mounting investor confidence in the company's expanding neuroscience pipeline and sleep-medicine franchise.

Amneal Pharmaceuticals (AMRX) surged approximately 37% over the last 30 days, climbing from around $11.81 on May 19 to $16.21 as of June 18, 2026. The rally was fueled by a strong Q1 2026 earnings beat, the transformative $1.1 billion acquisition of Kashiv BioSciences, and multiple FDA approvals.

Regencell Bioscience Holdings Limited (RGC) shares plunged about 14% in the most recent completed session, dropping to roughly $12.01 from above $14.The sell-off intensified after a wave of law-firm announcements highlighting a pending securities class action and potential DOJ-related investigations into the company’s disclosures and valuation.

TRLV surged approximately 42.6% over the last 30 days, driven by a historic NYSE uplisting and a $50 million share repurchase program. The stock rallied roughly 79% during the most recent quarter, reflecting improving fundamentals and regulatory tailwinds.

Regencell Bioscience Holdings shares tumbled approximately 11.54% in after-hours trading on June 17, 2026, extending a multi-day selloff. The primary catalyst is an intensifying legal storm — multiple securities class action lawsuits and a U.

Zoetis Inc. (ZTS) stock fell approximately 31% over the past 30 days, driven primarily by disappointing first-quarter 2026 earnings results and a lowered full-year guidance.

Hims & Hers Health reported Q1 2026 revenue of $608.1 million, up 4% year-over-year but missing estimates, with a surprise net loss of $92.1 million due to higher costs from shifting to branded GLP-1 (glucagon-like peptide-1) weight-loss drugs. Shares dropped over 14% post-earnings amid margin pressure, though the company raised full-year 2026 revenue guidance to $2.8–$3.0 billion.

Shares of HROW are plunging approximately 21.00% on Tuesday, May 12, 2026, falling from a Monday, May 11 close of $38.04 to approximately $30.05 — a severe earnings-driven selloff following Q1 2026 results released after Monday's close that delivered a deeply missed adjusted EPS of -$0.74 against a -$0.39 consensus estimate (a 90% miss),

HIMS shares are down approximately 15.15% in premarket trading on Tuesday, May 12, 2026, falling from Monday's closing price of $29.14 to around $24.73. The primary catalyst is a significant Q1 2026 earnings miss: the company reported an EPS loss of -$0.40, compared to the analyst consensus estimate of +$0.04 — swinging from a profit of $0.20 per share in Q1 2025.

Takeda to report FY2025 Q4 and full-year results on May 13, 2026, before U. S.

Analysts expect Q4 FY26 revenue of approximately $887 million, a potential decline due to softer U. S.

Analysts expect Q1 2026 revenue of approximately $617 million, up 5% from $586 million in Q1 2025. Consensus EPS estimate stands at $0.03, reflecting a sharp decline from $0.20 in the year-ago quarter amid higher costs.

ZTS shares plunged approximately 13.81% in premarket trading on May 7, 2026, falling from a prior close of $111.22 to around $95.86. The primary catalyst was a disappointing Q1 2026 earnings report released before the market open, with both revenue and adjusted EPS missing Wall Street consensus estimates.

TEVA stock surged approximately +20% over the past 30 days, driven primarily by strong Q1 2026 earnings that beat estimates and robust growth in branded drugs like AUSTEDO. The stock experienced volatility over the past quarter, ending roughly flat with a +3% gain amid broader market pressures and generics challenges, offset by innovative portfolio momentum.

Aurora Cannabis shares have shown volatility in recent weeks, trading near the lower end of their 52-week range amid broader sector pressures. Strategic acquisition of Safari Flower Company bolsters EU Good Manufacturing Practice (GMP) capacity for high-margin international medical sales.

CRDL stock surged +39% over the past 30 days, driven by positive Phase II ARCHER trial results publication and strong earnings beat. Over the past quarter, shares rose +34%, supported by Phase III MAVERIC trial enrollment milestones and $31 million in financing.

Teva Pharmaceutical Industries (TEVA), a global leader in generic and innovative medicines, does not pay a dividend. The company suspended dividends in December 2017 amid efforts to strengthen its balance sheet following high debt from past acquisitions. Prior to suspension, TEVA offered quarterly payments, with the last at $0.09 per share (ex-date November 27, 2017). Current dividend yield stands at 0%, and there is no forward dividend or scheduled ex-dividend date. This positions TEVA outside traditional dividend categories like high-yield or growth stocks, focusing instead on reinvestment for operational turnaround. From what I see, investors seeking immediate income should look elsewhere, but TEVA's robust cash generation signals potential for future policy shifts.

As Teva Pharmaceutical Industries (TEVA), a global leader in generic and innovative medicines, prepares to report first-quarter 2026 earnings on April 29, followed by a conference call at 8:00 a.m. ET, I'm paying close attention. This will be the first major update since full-year 2025 results, which delivered $17.3 billion in revenues, up 4% year-over-year, largely thanks to innovative products like AUSTEDO surpassing $2 billion annually. Investors like us will want to see clear progress on the "Pivot to Growth" strategy, especially as generics face headwinds, including a $1.1 billion impact from Revlimid in 2026. From what I see, shares have climbed significantly on prior beats—such as the +46% EPS surprise in Q4 2025—so this report could either reinforce momentum or highlight risks from pricing pressures and divestitures like the Japan operations.

I've been tracking TEVA, the stock of Teva Pharmaceutical Industries, as it builds a multi-year up-channel after reversing from a prolonged bottom. From what I see on the daily chart, the structure remains solidly bullish, with price having broken decisively above the 200-day moving average. Shorter-term, it holds an uptrend, positioned above most simple and exponential moving averages, such as the MA20 at $29.95 and MA50 at $29.52. A recent pullback has it testing dynamic support near the 20-day MA, which aligns with channel lows noted in trader analyses on platforms like TradingView. One thing that stands out is the declining volume during this consolidation, which often builds pressure for the next upward leg.